AJP Asia Intelligence Agency

Exploring Natural Products Research Institute in Gangneung for New Drugs and Cosmetics

On November 17, I visited the Natural Products Research Institute at the Korea Institute of Science and Technology (KIST) in Gangneung. This institute studies the efficacy of various native natural products in South Korea and develops cutting-edge raw materials for new drugs and cosmetics. Upon entering the institute's 'natural product library,' I was struck by the darkly lit walls filled with square frames.

Inside the frames were 1,013 species of plants displayed in their entirety, from roots to leaves. These natural products had completed technology transfer and patent registration and were stored as specimens.

A notable natural product was the native plant, astragalus, found in the Nocheonsan area of Gangneung. Park Jin-soo, the head researcher at the Natural Products System Biology Research Center, explained, "Various compounds have been discovered in astragalus, and among them, we found a component with anti-inflammatory effects, for which we have filed a patent application."

Natural products have fewer side effects and can be used for extended periods. Their range of applications has been broad, having been used in folk remedies for a long time. However, identifying and extracting the active ingredients can be challenging, requiring lengthy research periods.

The results of long-term research can be astonishing. Recently, the institute achieved notable results with 'astragalus.' Typically, astragalus roots are added when making samgyetang (ginseng chicken soup). The institute focused on 'astragalus sprouts.'

Park explained, "When we analyzed astragalus sprouts instead of the roots, we found beneficial components for skin beauty and whitening, and the patent has been completed. We expect technology transfer to be finalized within this year," adding that plans are in place to cultivate astragalus sprouts in smart farms for commercialization as cosmetic ingredients next year.

In the Hwanggye AI demonstration farm, similar initiatives were observed. The AI demonstration farm introduced 'hops,' known for their use in brewing. With high-value components identified in hops for skin care, the farm plans to mass-produce hops to verify their potential for high value. Currently, hops are not visible due to the cold weather, but they are expected to be seen around May next year.

Natural products are extracted and stored in vials under ultra-low temperatures to prevent changes in their composition. The extracted samples are stored in a database (DB) with identifiable information through barcodes. This is to test combinations with various natural products using artificial intelligence (AI) and to find components that maximize efficacy.

The institute has been early in adopting AI for research. The NPI Finder is a prime example. The NPI Finder allows researchers to simultaneously search for chemical components, protein targets, and disease information central to natural product research. Coupled with the evolutionary chemical bonding similarity (ECBS) prediction model, it enables rapid exploration of new disease applications for natural products.

Park Geun-wan, head researcher at the Natural Products Information Research Center, stated, "In the past, it took a long time to find active natural products and then isolate effective components. With the introduction of AI, we can now predict active ingredients and mechanisms of action first, leading to significant qualitative changes in our research."

The ECBS, which quickly explores compounds with similar functions, has gained international recognition. In the CACHE Challenge, an international competition for predicting AI-based new drug candidates, Park Geun-wan achieved joint victory in the third round and sole victory in the fourth round.

The Natural Products Research Institute also has an animal laboratory, where experiments are primarily conducted on mice. Mice breed quickly and have a close living radius to humans. Research on 'dry age-related macular degeneration eye drops' conducted by Seo Mun-hyung, head of the Natural Products Efficacy Optimization Research Center, also involved mouse experiments.

Age-related macular degeneration is a condition where abnormalities in the macula lead to decreased vision and distorted perception, primarily affecting the elderly. A treatment for the milder 'dry age-related macular degeneration' was first released in 2023 as an injection and is currently the only option available.

However, the injection has significant side effects. Seo focused on eye drops, particularly on the toll-like receptor (TLR) inflammatory signaling, identified as a major cause of macular degeneration. TLR protects our bodies through inflammatory responses, but if misregulated, excessive inflammation can occur.

Seo searched for substances that inhibit this signaling and developed a final peptide that can regulate it.

He verified the effectiveness of the discovered peptide by administering it to the eyes of mice induced with dry age-related macular degeneration over about three weeks, confirming its therapeutic potential. Seo anticipates completing toxicity tests by the first half of 2028, followed by clinical stages, with eye drops expected to be available around 2035.

Kim Joo-sun, director of the KIST Gangneung Natural Products Research Institute, commented, "The system of extracting natural products and synthesizing them into new drugs has been established. We expect a global blockbuster drug to be released in the market soon."




* This article has been translated by AI.